Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

RDHL vs BGM: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

BGM Wins Head-to-Head Institutional Verdict (4–1 across 6 Pillars · 6–2 Matrix Metrics)

BGM Overall Winner 6-Pillar Tally: RDHL 1 – 4 BGM (1 Tie) Matrix Metrics: RDHL 2 – 6 BGM

As of Nov 20, 2026, BGM Group Ltd. Class A (BGM) is the stronger overall head-to-head candidate over Redhill Biopharma Ltd. (RDHL) in the Tradestie Institutional Equity Comparison Engine, winning 6–2 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Balance Sheet & Cash Flow). RDHL carries a Unified Composite Score of 39.7/100 (SELL) at $0.28 (N/M Forward P/E, 0.0% operating margin), whereas BGM carries 59.6/100 (HOLD) at $8.00 (N/M Forward P/E, -23.4% operating margin).

  • Technical & Structure Timing Caution: RDHL is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 25.6); meanwhile BGM trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 53.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About RDHL vs BGM
RDHL NASDAQ
Redhill Biopharma Ltd.
Pharmaceutical Preparations
$0.28
-13.08% 1D
Market Cap $2.9M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.55β · 87% Vol
Unified Composite Score
39.7 / 100 SELL
Tech 25.0 Fund 45.0 Flow 50.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -19.4%), weak momentum, RSI 26
RSI-14: 25.6 · SMA20: $0.39 · SMA50: $0.46
BGM NASDAQ Head-to-Head Winner
BGM Group Ltd. Class A Ordinary Shares
Pharmaceutical Preparations
$8.00
-1.6% 1D
Market Cap $108.6M
TTM Revenue $48M
Forward P/E N/M
Beta / 30D Vol 3.69β · 80% Vol
Unified Composite Score
59.6 / 100 HOLD
Tech 65.0 Fund 55.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (167.7% over 20 days), RSI 54
RSI-14: 53.8 · SMA20: $8.51 · SMA50: $5.25

6-Pillar Scorecard Institutional Category Breakdown (RDHL 1 – 4 BGM)

Columns: Metric · RDHL · BGM
1. Valuation Multiples BGM
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M 2.3x
2. Growth & Scale BGM
Revenue Growth (YoY) +58.6% +69.8%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A $48M
Market Cap $2.9M $108.6M
3. Profitability & Quality RDHL
Gross Margin N/A 16.9%
Operating Margin 0.0% -23.4%
Net Profit Margin 0.0% -44.2%
Return on Equity (ROE) -1708.6% -7.4%
4. Balance Sheet & Cash Flow BGM
Cash Generation (TTM) N/A -$9.2M EBITDA
Cash Flow Margin N/A -19.3% EBITDA Mgn
Net Cash / Leverage $0.84 Book/Sh · -1708.6% ROE $59.55 Book/Sh · -7.4% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew Thin ADR Chain N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markup
6. R&D & Supply-Chain Moat BGM
OpEx & R&D Intensity N/A 40.3% of Rev ($19M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Drug Manufacturers - Specialty & Generic Operator Drug Manufacturers - Specialty & Generic Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: RDHL (2) vs BGM (6)
Institutional Metric RDHL BGM Criterion Row Edge
Market Capitalization
Scale
$2.9M $108.6M Larger Scale BGM
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+58.6% +69.8% Higher Growth BGM
Operating Margin (TTM)
Profitability
0.0% -23.4% Higher Margin RDHL
Net Profit Margin
Profitability
0.0% -44.2% Higher Margin RDHL
Return on Equity (ROE)
Capital Efficiency
-1708.6% -7.4% Higher ROE BGM
52-Week Range Position
Momentum
0% ($0–$2) 74% ($0–$11) Stronger Trend BGM
Beta / 30D Volatility
Risk Regime
0.55β · 87% Vol 3.69β · 80% Vol Lower Realized Risk BGM
Unified Institutional Score
Composite Signal
39.7 / 100 (SELL) 59.6 / 100 (HOLD) Higher Composite BGM
Trailing 12M Revenue (USD)
Operating Scale
N/A $48M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 16.9% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 2.3x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A ($0.84 Book/Sh · -1708.6% ROE) -$9.2M EBITDA ($59.55 Book/Sh · -7.4% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon BGM +17.82 pp
RDHL: -39.39% · BGM: -21.57%
3M Horizon BGM +2719.13 pp
RDHL: -45.2% · BGM: +2673.93%
6M Horizon BGM +3031.09 pp
RDHL: -68.3% · BGM: +2962.79%
1Y Horizon BGM +63.14 pp
RDHL: -68.91% · BGM: -5.77%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on RDHL vs BGM. Trailing 12-month operating profitability (RDHL 0.0% vs BGM -23.4%) and valuation multiples (RDHL N/M vs BGM N/M Forward P/E) are benchmarked directly in Pillar 4 below.

RDHL ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-1708.6% · N/M
BGM ADR TTM Benchmark FX-Normalized USD
TTM Revenue$48M
Gross Margin16.9%
Op. Margin-23.4%
ROE / Fwd P/E-7.4% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
RDHL UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew Thin ADR Chain
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact RDHL Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
BGM UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact BGM Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
RDHL Moat Profile Cyclical / Execution-Driven Positioning
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $2.9M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
BGM Moat Profile Cyclical / Execution-Driven Positioning
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $108.6M market capitalization and -23.4% operating margin.
OpEx & R&D Reinvestment 40.3% of Rev ($19M)
90D Engineering Disclosures 0 Published

Investor FAQ RDHL vs BGM Key Questions & Quantitative Answers

As of Nov 20, 2026, BGM Group Ltd. Class A (BGM) is the stronger overall head-to-head candidate over Redhill Biopharma Ltd. (RDHL) in the Tradestie Institutional Equity Comparison Engine, winning 6–2 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Balance Sheet & Cash Flow). RDHL carries a Unified Composite Score of 39.7/100 (SELL) at $0.28 (N/M Forward P/E, 0.0% operating margin), whereas BGM carries 59.6/100 (HOLD) at $8.00 (N/M Forward P/E, -23.4% operating margin). Technical & Structure Timing Caution: RDHL is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 25.6); meanwhile BGM trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 53.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

BGM leads the Growth & Scale pillar: RDHL posts +58.6% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with BGM at +69.8% YoY revenue growth and +0.0% YoY earnings growth on $48M TTM revenue (16.9% gross margin, -23.4% operating margin). On trailing 12-month operating scale, RDHL generates N/A in USD-normalized revenue versus $48M for BGM. In operating R&D and SG&A reinvestment, RDHL deploys N/A (0 90-day corporate R&D disclosures) versus 40.3% of Rev ($19M) (0 disclosures) for BGM.

BGM screens cheaper on headline valuation multiples. RDHL trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas BGM trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 2.3x EV/Revenue (-19.3% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against RDHL (-1708.6% ROE) versus BGM (-7.4% ROE) capital efficiency.

In options market volatility and institutional positioning, RDHL carries N/A implied volatility (N/A, Unclassified), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.55β · 87% Vol realized risk). By comparison, BGM carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (3.69β · 80% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.